IDYA IDEAYA Biosciences
- 40.250
- -0.390-0.96%
IDEAYA Biosciences News
Buy Rating Affirmed for IDEAYA Biosciences Amid Promising Clinical Updates and Pipeline Catalysts
Unveiling 5 Analyst Insights On IDEAYA Biosciences
In the preceding three months, 5 analysts have released ratings for IDEAYA Biosciences (NASDAQ:IDYA), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates t
IDEAYA Biosciences Price Target Maintained With a $52.00/Share by Wedbush
IDEAYA Biosciences Price Target Maintained With a $52.00/Share by Wedbush
Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $52 Price Target
Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences with a Outperform and maintains $52 price target.
IDEAYA Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 23.77% Wedbush → $52 Reiterates Outperform → Outperform 03/21/2024 42.81% Citigroup $40 → $60 M
Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $50, Maintains Outperform Rating
IDEAYA Biosciences (IDYA) has an average rating of Buy and price targets ranging from $50 to $60, according to analysts polled by Capital IQ.
IDEAYA Biosciences (IDYA) Receives a Buy From Wedbush
Buy Rating Affirmed: IDEAYA Biosciences' Promising Pipeline and Strong Financial Position
Analysts' Top Healthcare Picks: IDEAYA Biosciences (IDYA), Surgery Partners (SGRY)
IDEAYA Biosciences | 10-Q: Quarterly report
IDEAYA Biosciences Says $941.4M Of Cash, Cash Equivalents And Marketable Securities As Of March-End, Anticipated To Fund Operations Into 2028
IDEAYA Biosciences Says $941.4M Of Cash, Cash Equivalents And Marketable Securities As Of March-End, Anticipated To Fund Operations Into 2028
IDEAYA Biosciences Q1 2024 GAAP EPS $(0.53), Inline
IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(0.53) per share which met the analyst consensus estimate.
IDEAYA Biosciences: Runway to Fund Operations Into 2028 >IDYA
IDEAYA Biosciences: Runway to Fund Operations Into 2028 >IDYA
IDEAYA Biosciences 1Q Loss $39.6M >IDYA
IDEAYA Biosciences 1Q Loss $39.6M >IDYA
Press Release: IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., May 7, 2024 -- ASCO 2024 oral presentation of darovase
IDEAYA Biosciences 1Q Loss/Shr 53c >IDYA
IDEAYA Biosciences 1Q Loss/Shr 53c >IDYA
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
SOUTH SAN FRANCISCO, Calif., May 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeu
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation For Darovasertib In Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDTThe abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ETSOUTH SAN FRANCISCO, Calif., April 24, 20
IDEAYA Biosciences Has Selected Move-Forward Phase 2 Expansion Dose For IDE397 Monotherapy In MTAP-Deletion Squamous Non-small Cell Lung Cancer, Based On The Adverse Event Profile And Preliminary Clinical Efficacy
Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial respon
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1.1
Analysis
Price Target
No Data
